XML 82 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8
ALLIANCES AND COLLABORATIONS (Pfizer) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Dec. 31, 2012
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Net Sales $ 4,048 $ 4,443 $ 7,879 $ 9,694  
Deferred income 5,132   5,132   4,849
Eliquis [Member]
         
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Net Sales 12 1 34 1  
Pfizer [Member] | Eliquis [Member]
         
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Net Sales   1   1  
Profit sharing expense 6   16    
Commercialization expense reimbursements to/(from) Pfizer (5) (3) (17) (8)  
Research and development reimbursements to/(from) collaboration partner 2 9 9 11  
Maximum percentage of reimbursement for development costs from collaboration 60.00%   60.00%    
Minimum percentage of reimbursement for development costs from collaborations 50.00%   50.00%    
Pfizer [Member] | Eliquis [Member] | Upfront, milestone and other licensing payments [Member]
         
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total upfront, milestone and other licensing payments received 684   684    
Potential additional development and regulatory milestone receipts 200   200    
Amortization income - upfront, milestone and other licensing payments (9) (9) (19) (19)  
Upfront, milestone and other licensing payments received     125    
Deferred income   $ 503   $ 503 $ 397